Comparison · NCT01782443-sae
Ziv-aflibercept 4mg/kg vs Ziv-aflibercept 2mg/kg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ziv-aflibercept 4mg/kg vs Ziv-aflibercept 2mg/kg: serious adverse events. Trial comparisons, record NCT01782443-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01782443-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.237 | 0.763 | wilson | |
| Risk in group 2 | 0.556 | 0.267 | 0.811 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0556 | -0.423 | 0.335 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.9 | 0.384 | 2.11 | log | |
| Odds ratio, group 1 over group 2 | 0.8 | 0.131 | 4.87 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ziv-aflibercept 4mg/kg than on Ziv-aflibercept 2mg/kg | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ziv-aflibercept 4mg/kg | Patients treated with a starting dose of Ziv-aflibercept 4 mg/kg | 5 | 10 | EG000 |
| Group 2 | Ziv-aflibercept 2mg/kg | Patients treated with a starting dose of Ziv-aflibercept 2 mg/kg | 5 | 9 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Patients were followed for AEs from first dose of study treatment, throughout the study, and through 30 days of the last study treatment, an average of 16 months. Participants removed from study for unacceptable adverse events were followed until resolution or stabilization of the adverse event.
Source ClinicalTrials.gov
Trial
- Title
- Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
- NCT number
- NCT01782443
- Phases
- PHASE2
- Conditions
- Carcinoid Tumor
- Interventions
- Ziv-aflibercept
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2022-11-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01782443?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01782443-sae